Bailard’s United Therapeutics UTHR Stock Holding History

Bailard’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,800	Closed	-$414K	–	511
2017 Q4	$414K	Buy	+2,800	New	+$356K	0.03%	334

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JIM

Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Bailard's UTHR Position: Q1 2018 in Review

Bailard sold out of United Therapeutics (UTHR) in Q1 2018, closing a stake of 2,800 shares — an estimated $414K sold.

Bailard first reported a position in UTHR in Q4 2017 and held it in 1 quarter. The position peaked at $414K in Q4 2017. 374 funds tracked by Wall St. Rank hold UTHR as of Q1 2018.

Bailard reported no remaining United Therapeutics position as of Q1 2018 after selling out during the quarter.
Bailard sold 2,800 United Therapeutics shares in Q1 2018, an estimated $414K.
Bailard first reported a position in United Therapeutics in Q4 2017 and held it in 1 quarter.
Bailard's United Therapeutics position peaked at $414K in Q4 2017.
374 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2018.

Based on Bailard's 13F filing for Q1 2018, filed 7 May 2018.